Regulation of Dual-Specificity Phosphatase (DUSP)
Ubiquitination and Protein Stability

Hsueh-Fen Chen, Huai-Chia Chuang * and Tse-Hua Tan *

Immunology Research Center, National Health Research Institutes, Zhunan 35053, Taiwan; 061013@nhri.edu.tw
* Correspondence: cinth@nhri.edu.tw (H.-C.C.); ttan@nhri.edu.tw (T.-H.T.); Tel.: +886-37-246166 (ext. 37612) (H.-C.C.); +886-37-246166 (ext. 37601) (T.-H.T.); Fax: +886-37-586642 (H.-C.C.); +886-37-586642 (T.-H.T.)

Received: 29 April 2019; Accepted: 29 May 2019; Published: 30 May 2019

Abstract: Mitogen-activated protein kinases (MAPKs) are key regulators of signal transduction and cell responses. Abnormalities in MAPKs are associated with multiple diseases. Dual-specificity phosphatases (DUSPs) dephosphorylate many key signaling molecules, including MAPKs, leading to the regulation of duration, magnitude, or spatiotemporal profiles of MAPK activities. Hence, DUSPs need to be properly controlled. Protein post-translational modifications, such as ubiquitination, phosphorylation, methylation, and acetylation, play important roles in the regulation of protein stability and activity. Ubiquitination is critical for controlling protein degradation, activation, and interaction. For DUSPs, ubiquitination induces degradation of eight DUSPs, namely, DUSP1, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, and DUSP16. In addition, protein stability of DUSP2 and DUSP10 is enhanced by phosphorylation. Methylation-induced ubiquitination of DUSP14 stimulates its phosphatase activity. In this review, we summarize the knowledge of the regulation of DUSP stability and ubiquitination through post-translational modifications.

Keywords: dual-specificity phosphatase; mitogen-activated protein kinase; ubiquitination; protein stability

1. The DUSP Family Phosphatases

Mitogen-activated protein kinases (MAPKs) are the important components of cell signaling pathways. MAPKs regulate physiological and pathological responses to various extracellular stimuli and environmental stresses [1–7]. The best-known members of the MAPK family are ERK, JNK, and p38 subgroups [5,6]. These kinases unusually require dual phosphorylation on both threonine and tyrosine residues within the conserved motif T-X-Y for kinase activity [8]. The MAPK signaling pathways are involved in the processes of gene transcription, mRNA translation, protein stability, protein localization, and enzyme activity, thus regulating various cellular functions including cell proliferation, cell differentiation, cell survival, and cell death [9,10]. MAPK signaling pathways are also involved in a number of diseases including inflammation and cancer [11,12]. Pathway outputs reflect the balance between the activation of upstream pathways and the inhibition of negative regulators. Inactivation of MAPKs are mediated by serine/threonine phosphatases, tyrosine phosphatase, and dual-specificity phosphatases (DUSPs) through dephosphorylation of threonine and/or tyrosine residues of the T-X-Y motif within the kinase activation loop [13]. The largest group of protein phosphatases that specifically regulates the MAPK activity in mammalian cells is the DUSP family phosphatases [13].

The DUSP family phosphatases dephosphorylate both threonine/serine and tyrosine residues of their substrates. All DUSPs have a common phosphatase domain, which contains conserved Asp, Cys, and Arg residues forming the catalytic site. A subfamily of DUSPs contains the MAP kinase-binding (MKB) motif or the kinase-interacting motif (KIM) that interacts with the common docking domain of MAPKs to mediate the enzyme–substrate interaction [14,15]. DUSPs containing the KIM domain are
DUSPs do not always require phosphatase activity to regulate the function of substrates. For example, DUSPs can control functions of MAPKs by sequestering them in the cytoplasm or nucleus [16–18]. Because both DUSPs and substrates of MAPKs interact with MAPKs via the common docking domain of MAPKs [19], DUSPs may also regulate MAPK signaling by competing with MAPK substrates for binding to MAPKs [15].

DUSPs are critical for the regulation of MAPK activity and are thus subject to complex regulation. Gene expression and phosphatase activity of DUSPs are regulated by gene transcription, protein modification, or protein stability. This review will focus on the regulation of DUSP protein stability and ubiquitination by post-translational modifications.

| Classification | Gene Symbol | Domain Structure | MAPK Substrates |
|----------------|-------------|------------------|-----------------|
| Typical DUSPs  | DUSP1       | MKP1, CL100, VH1, HVH1, PTPN10 | JNK, p38 > ERK |
| (also named MKPs) | DUSP4       | MKP2, VH2, HVH2, TYP | ERK, JNK > p38 |
| Typical DUSPs  | DUSP6       | MKP3, PYST1 | ERK |
| (not named as MKPs) | DUSP7       | PYST2, MKP7 | ERK |
|                  | DUSP9       | MKP4 | ERK > p38 |
|                  | DUSP10      | MKP5 | JNK, p38 |
|                  | DUSP14      | MKP6, MKP-L | JNK (p38) |
|                  | DUSP16      | MKP7 | JNK (p38) |
|                  | DUSP18      | DUSP20, LMW-DSP20 | ERK, JNK, p38 |
|                  | DUSP19      | DUSP17, LMW-DSP3, SKRP1, TS-DSP1 | ERK |
|                  | DUSP21      | LMW-DSP21 | ERK |
|                  | DUSP23      | JKP3, SP1, VHX, LMW-DSP2, MKP3 | JNK, p38 > ERK |
|                  | DUSP24      | DUSP25, VH2, LDP-3, MOSP | JNK > ERK > p38 |
|                  | DUSP25      | SKRP1, TS-DSP1 | p38 (ERK?) |
|                  | DUSP26      | MKP9, LDP-4, NATAX1, SKRP3, NEAP, DUSP26 | p38 (ERK?) |

*MKPX is a duplicate name for both DUSP7 and DUSP22. **DUSP24 and DUSP26 are renamed to DUSP26 and DUSP28, respectively. Domain structures are annotated from the Ensemble database.

Table 1. Classification and domain structure of human dual-specificity phosphatases (DUSPs).
2. Negative Regulation of DUSPs by Lys48-Linked Ubiquitination and Proteasomal Degradation

Ubiquitination regulates many biological functions such as cell proliferation, cell apoptosis, and immune responses [20]. Ubiquitination is the modification of a protein by ubiquitin(s) on one or more lysine residues. Ubiquitination is mediated by an enzyme cascade involving three classes of enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase), resulting in covalent bonding of ubiquitin to lysine residues of protein substrates [21]. Ubiquitin contains seven lysine residues (Lys6, 11, 27, 29, 33, 48, and 63) that can act as ubiquitin acceptor forming ubiquitin chains with different topologies on protein substrates. The functions of Lys48-linked and Lys63-linked ubiquitinations are well characterized. Lys48-linked ubiquitination primarily controls proteasomal degradation; Lys63-linked ubiquitination controls several protein functions, including receptor endocytosis, protein trafficking, enzyme activity, and protein–protein interaction [22]. In addition, Lys48- and Lys63-linked ubiquitinations are associated with lysosomal degradation [23].

DUSP1 (MKP1) is a nuclear phosphatase [24]. DUSP1 binds to JNK and p38 with stronger affinity compared to its binding to ERK, leading to their dephosphorylation and inactivation [25]. Reciprocally, ERK induces DUSP1 proteasomal degradation by enhancing nuclear translocation and transcription activity of the transcription factor forkhead box M1 (FoxM1) [26], leading to the induction of the ubiquitin E3 ligase complex S-phase kinase-associated protein (Skp2)/cyclin-dependent kinase regulatory subunit 1 (Cks1) [27–30]. Besides ERK, other signaling molecules also control DUSP1 degradation. DUSP1 underwent an ubiquitin-mediated proteasomal degradation in response to glutamate-induced oxidative stress [31]. The involved E3-ubiquitin ligase was not identified; however, the process depends on the presence of PKCδ [31]. EGF plus lactoferrin induce a rapid proteasomal degradation of DUSP1, resulting in sustained ERK activation in human fibrosarcoma [32]. In rat cardiac myoblast H9c2 cells, the ubiquitin E3 ligase Atrogin-1 interacts with DUSP1 and promotes the ubiquitin-mediated proteasomal degradation of DUSP1, thereby leading to sustained activation of JNK signaling and subsequent cell apoptosis and ischemia/reperfusion injury [33]. Conversely, ubiquitin-specific peptidase 49 (USP49; a deubiquitinase) interacts with and deubiquitinates DUSP1, resulting in DUSP1 stabilization [34]. Angiotensin II-stimulated proteasome activity results in DUSP1 degradation and subsequent STAT1 activation in T cells, leading to induction of Th1 differentiation [35]; however, it is unclear how DUSP1 is regulated by angiotensin II. DUSP1 knockdown results in prolonged and enhanced STAT1 phosphorylation; it remains unclear whether DUSP1 can directly dephosphorylate STAT1.

DUSP4 (MKP2) preferentially inhibits ERK and JNK [36]. In senescent human fibroblasts, the phosphatase activity and protein levels of DUSP4 are increased due to impaired proteasomal activity [37]. 8-Bromo-cAMP (8-Br-cAMP) stimulation leads to reduction of the proteasomal degradation of DUSP4 in Leydig cells [38]; DUSP4 stabilization results in inhibition of ERK activity and subsequent reduction of the synthesis of P450scc steroidogenic enzyme, which is critical for steroid synthesis [38].

DUSP5 displays phosphatase activity toward ERK; DUSP5 overexpression results in both inactivation and nuclear translocation of ERK [16]. DUSP5 is a short-lived protein, which is ubiquitinated and subjected to proteasomal degradation [39]. DUSP5 degradation enhances the amplitude and duration of ERK signaling [40]. Reciprocally, ERK induces DUSP5 stability by decreasing DUSP5 ubiquitination [39]; the regulation is independent of ERK kinase activity but dependent on ERK–DUSP5 interaction [39].

DUSP6 (MKP3) preferentially inhibits ERK [41,42]. Reduction of DUSP6 by reactive oxygen species (ROS) is correlated with high ERK activity [43]. Similarly, in thyrocytes, B-Raf (V600E) mutation induces ROS generation, leading to proteasomal degradation of DUSP6 [44]. The B-Raf (V600E)-induced DUSP6 degradation results in ERK activation and cell senescence [44]. The anti-diabetic drug metformin accelerates the development of B-Raf (V600E)-mediated melanoma by inducing proteasomal degradation of DUSP6 through AMPK [45]. In breast cancer cells, PKCδ depletion results in ERK activation by inducing the level of the ubiquitin E3 ligase Nedd4, which induces DUSP6 degradation [46].
In contrast, thyroid-stimulating hormone (TSH) stabilizes DUSP6 by enhancing the expression of manganese superoxide dismutase (MnSOD), leading to prevention of senescence and induction of papillary thyroid carcinoma [44].

DUSP7, an ERK phosphatase, is ubiquitinated under hypoxic stress [47]. Hypoxia-inducible factors (HIFs) induce expression and cytoplasmic accumulation of the ubiquitin E3 ligase speckle-type POZ protein (SPOP) in clear cell renal cell carcinoma under hypoxic stress [47]. SPOP induces tumorigenesis by promoting ubiquitination and degradation of multiple regulators, including DUSP7 [47].

DUSP8 (M3/6) preferentially inactivates JNK and maybe p38 [48–50]. The protein synthesis inhibitor anisomycin [51] enhances the JNK pathway via activation of its upstream kinase SEK/MKK4 [52]. Anisomycin also stimulates JNK activity by inducing ubiquitination and degradation of DUSP8 [52]. In contrast, the proteasome inhibitor lactacystin prevents DUSP8 degradation, resulting in dephosphorylation and inactivation of JNK [52].

DUSP9 (MKP4), an ERK phosphatase, is associated with maintenance of the stemness of embryonic stem cells (ESCs) [53]. The long non-coding RNA (lncRNA) LincU directly binds and protects the DUSP9 protein from ubiquitin-mediated proteasomal degradation; the stabilized DUSP9 inhibits ERK activation, leading to preservation of naïve pluripotency of ESCs [53].

DUSP16 is also regulated by ubiquitin-mediated proteasomal degradation, and their ubiquitinations are regulated by phosphorylation (see below). In addition to Lys48-linked ubiquitination, one DUSP (DUSP14) is regulated by Lys63-linked ubiquitination (see Section 3.3).

3. Other Post-Translational Regulations of DUSP Ubiquitination and/or Stability

3.1. Phosphorylation

DUSP1 stability is differentially regulated by sustained or transient activation of ERK. Sustained activation of ERK phosphorylates DUSP1 on Ser296 and Ser323 residues [54]. The Ser296/323 phosphorylation of DUSP1 facilitates its interaction with the ubiquitin E3 ligase CUL1/SKP2/CKS1 complex, which targets DUSP1 for proteasomal degradation [27,54,55]. In contrast, ERK reduces DUSP1 degradation by phosphorylating two other residues, Ser359 and Ser364 [56,57]. Transient activation of ERK stimulates DUSP1 Ser359/364 phosphorylation, which enhances DUSP1 stability, and feedback attenuates ERK signaling [56]. One group reported that this ERK-induced DUSP1 stabilization may be independent of ubiquitination [57]. Furthermore, Krüpple-like transcription factor 5 (KLF5) promotes breast cancer cell survival partially through ERK-induced DUSP1 Ser359/364 phosphorylation, which is essential for DUSP1 protein stabilization [58].

DUSP1 stabilization results in inhibition of JNK and p38 activation, as well as subsequent inhibition of TNF-α and IL-6 production [59]. Glucocorticoids prevent animals from autoimmune diseases due to enhancement of DUSP1 expression and stability [60–62]. Insulin stimulation enhances DUSP1 phosphorylation, resulting in DUSP1 stabilization in vascular smooth muscle cells (VSMCs) [63]. This increase of DUSP1 leads to reduction of ERK activity and subsequent inhibition of cell migration [63]. The phosphorylated calcium/calmodulin kinase II (CaMKII) interacts with DUSP1 and prevents DUSP1 from proteasomal degradation [64]. Conversely, dephosphorylation of CaMKII leads to disruption of CaMKII–DUSP1 interaction, leading to proteasome degradation of DUSP1 [64].

DUSP2 stability is induced by the atypical MAP kinase ERK4 [65]. Wild-type ERK4, but not catalytically inactive ERK4, binds to and stabilizes DUSP2 proteins [65]. This finding suggests that DUSP2 may be phosphorylated by ERK4, leading to DUSP2 stabilization.

DUSP4 is rapidly induced after ERK activation [66]. ERK interacts with and phosphorylates DUSP4 on Ser386 and Ser391 residues within the C-terminus [67], leading to prevention of DUSP4 from ubiquitin-mediated proteasomal degradation. The mechanism provides a negative feedback control of ERK activity [67,68]. Consistently, a short spliced isoform (encoding 303 amino acids) of human DUSP4 lacking the MAP kinase binding site is more susceptible to ubiquitination and proteasomal
degradation than that of DUSP4 [69]. It is noted that one group reported no detectable effect of ERK on DUSP4 ubiquitination [57].

DUSP6 can also be a substrate of ERK. Upon serum stimulation, ERK phosphorylates DUSP6 on Ser159 and Ser197 residues in fibroblast cells [70]. The ERK-induced DUSP6 phosphorylation triggers ubiquitination and proteasomal degradation of DUSP6 [70]. EGF plus lactoferrin induce proteasomal degradation of DUSP6 [32]. P2X7 nucleotide or EGF also stimulates DUSP6 Ser197 phosphorylation by ERK, resulting in proteasomal degradation of DUSP6 in neurons and astrocytes [71]. Thus, ERK exerts a positive-feedback mechanism on its own kinase activity by promoting the degradation of DUSP6 [70,71]. In addition, insulin induces DUSP6 degradation through the ERK-mediated DUSP6 Ser159/197 phosphorylation in liver cells [72]. The reduction of DUSP6 by insulin signaling leads to downregulation of glucose-6-phosphatase, resulting in inhibition of glucose output of liver cells [72].

In addition to ERK-mediated degradation of DUSP6, mTOR signaling also induces the phosphorylation of DUSP6 on Ser159 residue and its subsequent proteasomal degradation [73]. Intracellular reactive oxygen species (ROS) accumulation such as hydrogen peroxide causes DUSP6 phosphorylation on Ser159 and Ser197 residues, leading to ubiquitination and degradation of DUSP6 in ovarian cancer cells [43].

DUSP6 is ubiquitinated and degraded by proteasome in the early phase of platelet-derived growth factor-B chains (PDGF-BB) stimulation; the process requires MEK-induced phosphorylation of DUSP6 on Ser174 residue [74]. In the later phase, DUSP6 is induced by ERK-mediated transcriptional expression, leading to inhibition of ERK activity [74]. Interestingly, both protein degradation and mRNA synthesis of DUSP6 are ERK-dependent, indicating both positive and negative regulation of DUSP6 by ERK [74]. Therefore, the regulation of DUSP6 by PDGF-BB stimulation exhibits a negative feedback control of PDGF-BB signaling [74].

DUSP10 is phosphorylated by mTORC2 on Ser224 and Ser230 residues upon insulin stimulation, leading to stabilization of DUSP10 and subsequent inactivation of p38 in glioblastoma cells [75].

DUSP16 preferentially inactivates JNK [17] and maybe p38 [76]. ERK phosphorylates Ser446 residue of DUSP16, resulting in enhancement of DUSP16 protein stability [77]. DUSP16 protein levels are rapidly decreased by ubiquitination and subsequent proteasomal degradation in quiescent cells [77]. ERK also phosphorylates DUSP16 on Ser446 residue [77,78]. This phosphorylation leads to stabilization of DUSP16 by preventing ubiquitination [77]. Induction of DUSP16 strongly suppresses JNK activation. Therefore, the activation of the ERK pathway can strongly inhibit JNK activation by stabilizing DUSP16 [77,78].

3.2. Oxidation

DUSP1 and DUSP4 proteins can be oxidized under oxidative stress. Oxidation of catalytic cysteine within the active site of DUSPs inactivates DUSP phosphatase activities and triggers their proteasomal degradation [55,79]. Superoxide induces DUSP1 proteasomal degradation, leading to JNK activation and subsequent cell death in lung cancer cells [80]. Metabolic disorder-induced oxidative stress causes DUSP1 S-glutathionylation and subsequent proteasomal degradation of DUSP1, resulting in macrophage migration and macrophage recruitment [81]. In addition, oxidation of DUSP1 induces its proteasomal degradation in monocytes upon asbestos stimulation, leading to induction of p38 activity and TNFα gene expression [82].

DUSP4 is redox sensitive. Under cadmium ion (Cd²⁺)-induced oxidative stress, DUSP4 is oxidized by glutathione disulfide (GSSG), leading to DUSP4 degradation and cell apoptosis [83]. In contrast, N-acetylcysteine (NAC) treatment upregulates the protein levels of DUSP4, protecting cells from cadmium ion (Cd²⁺)-induced apoptosis [83].

3.3. Methylation

DUSP14 (MKP6) is a MAP kinase phosphatase that inactivates JNK, ERK, and p38 in vitro [84]. DUSP14 is a negative regulator of T-cell receptor (TCR) signaling by directly inhibiting ERK in T
cells [84]. DUSP14 also attenuates T-cell activation by directly dephosphorylating TAB1, leading to inhibition of TAB1–TAK1 complex and its downstream signaling molecules JNK and IKK [85]. Upon TCR signaling, DUSP14 interacts with the ubiquitin E3 ligase TRAF2, which promotes Lys63-linked ubiquitination on Lys103 residue of DUSP14 [86]. DUSP14 Lys63-linked ubiquitination is induced by methylation [87]. During TCR signaling, protein arginine methyltransferase 5 (PRMT5) interacts with DUSP14 and triggers its methylation on Arg17, Arg38, and Arg45 residues [87]. DUSP14 contains a TRAF2-binding motif, IAQIT, which is adjacent to these methylation sites. DUSP14 methylation results in recruitment of the ubiquitin E3 ligase TRAF2, which in turn induces Lys63-linked ubiquitination on Lys103 residue of DUSP14 [86,87]. Methylation and subsequent ubiquitination stimulate the phosphatase activity of DUSP14. Taken together, methylation-induced ubiquitination of DUSP14 promotes the activation of DUSP14 phosphatase activity during TCR signaling, resulting in attenuation of T-cell activation [85–87] (Figure 1).

![Figure 1](image-url)  
**Figure 1.** Upon T-cell receptor (TCR) signaling, the protein arginine methyltransferase PRMT5 interacts with DUSP14 and induces its methylation on Arg17, Arg38, and Arg45 residues. Arginine-methylated DUSP14 then interacts with the ubiquitin E3 ligase TRAF2, which binds to the motif containing IAQIT residues of DUSP14 and then promotes K63-linked ubiquitination on Lys103 residue of DUSP14. Methylation and subsequent ubiquitination enhance the phosphatase activity of DUSP14. Activated DUSP14 dephosphorylates TAB1, leading to sequential inactivation of TAK1 and downstream IKK/JNK activities. Activated DUSP14 also directly dephosphorylates ERK and attenuates the ERK signaling pathway. Arrows denote activation; T bars denote inhibition.

### 4. Dysregulation of DUSPs in Diseases

DUSPs are involved in immune cell homeostasis, inflammatory responses, metabolic regulation, and cancer development/progression [15,88]. For example, DUSP6 knockout mice show impaired T-cell glycolysis and increased T follicular helper cell (T_{FH}) differentiation [89]. DUSP6 knockout mice also show altered gut microbiome and transcriptome response against diet-induced obesity [90]. Moreover, DUSP6 downregulation is correlated with cancer progression of human pancreatic adenocarcinoma and lung cancer [91,92]. DUSP2 downregulation induces colon cancer stemness [93]. DUSP3 downregulation occurs in human non-small cell lung cancer patients [94]; consistently, DUSP3 deficiency results in enhanced cancer cell migration [95]. DUSP5 is also downregulated in human gastric and colorectal cancers [96,97]. In addition, DUSP22 knockout mice show enhanced T-cell-mediated immune responses and are more susceptible to experimental autoimmune encephalomyelitis (EAE) [98]; consistently, DUSP22 protein levels are decreased in T cells of human systemic lupus erythematosus (SLE) patients [99]. DUSP22 expression is also downregulated in human T-cell lymphoma [100,101]. Therefore, further studies of DUSP protein stability and/or ubiquitination may help understand the complex interplay between cell signaling pathways and disease pathogenesis.
5. Conclusions

The DUSP family phosphatases are key regulators of MAPK activity [13]. Because the half-lives of many DUSPs are only about 1 h, protein levels of DUSPs are tightly regulated by post-translational modifications [15]. The post-translational regulations of DUSP proteins are summarized in Figure 2. The studies for protein stability of DUSPs are summarized in Table 2.
Figure 2. Post-translational modifications regulate DUSP protein stability. (A) Ubiquitination, oxidation, Cys258 S-glutathionylation, or Ser296/Ser323 phosphorylation of DUSP1 induces DUSP1 proteasomal degradation. Deubiquitination or phosphorylation of Ser359 and Ser364 residues enhances DUSP1 protein stability. (B) ERK induces DUSP2 protein stabilization; however, it is unclear whether ERK directly phosphorylates DUSP2. Phosphorylation of Ser386 and Ser391 residues of DUSP4 enhances its protein stability by inhibiting ubiquitin-mediated proteasomal degradation. Oxidation induces DUSP4 protein degradation. Reduced ubiquitination of DUSP5 enhances its protein stability. (C) Phosphorylation of Ser159, Ser174, or Ser197 residue induces proteasomal degradation of DUSP6. (D) Ubiquitination of DUSP7 or DUSP8 induces their proteasomal degradation. (E) Reduced ubiquitination of DUSP9 or DUSP16 enhances their protein stability. Phosphorylation of Ser224 and Ser230 residues enhances DUSP10 protein stability. Ub denotes ubiquitination of DUSPs. Oxidation indicates oxidation of DUSP1 or DUSP4.
Table 2. Regulation of DUSP protein stability or phosphatase activity.

| Stimuli                  | Stability | Modification | Modification Enzyme | Experimental Methods | Ubiquitination | Proteasome Inhibitor | Reference       |
|--------------------------|-----------|--------------|---------------------|----------------------|----------------|----------------------|-----------------|
|                          |           |              |                     |                      |                |                      |                 |
| DUSP1                    | Serum     | ↓            | Phosphorylation† (human Ser296 †/Ser323 †); Ubiquitination† | ERK, CUL1            | ✓              | ✓                    | LLnL; MG132     | [28,54]         |
|                          | Estradiol | ↑            | Phosphorylation† (human Ser539 †/Ser364 †) | ERK                  | ✓              | ✓                    |                 | [56]            |
|                          | LPS       | ↑            | Phosphorylation† (human Ser539 †/Ser364 †) | ERK                  | ✓              | ✓                    |                 | [57]            |
|                          | Pb2⁺      | ↓            | Ubiquitination†     | ERK                  | ✓              | ✓                    |                 |                 |
|                          | Glutamate/ PKCδ | ↓ | Ubiquitination† | ERK                  | ✓              | ✓                    |                 |                 |
|                          | Atrogin-1 upregulation | ↓ | Ubiquitination† | Atrogin-1           | ✓              | ✓                    | MG132           | [33]            |
|                          | USP49 upregulation | ↑ | Ubiquitination† | USP49               | ✓              | ✓                    | MG132           | [34]            |
|                          | KLF5 upregulation | ↑ | Phosphorylation† (human Ser539 †/Ser364 †) | ERK                  | ✓              | ✓                    | MG132           | [58]            |
|                          | LPS       | ↑            | Phosphorylation† (human Ser539 †/Ser364 †) | ERK                  | ✓              | ✓                    |                 |                 |
|                          | Insulin   | ↑            | Phosphorylation†    | ERK                  | ✓              | ✓                    | MG132, Lactacystin | [63]            |
|                          | Asbestos/ ROS | ↓ | Oxidation†       |                     | ✓              | ✓                    | MG132           | [82]            |
|                          | TNFa/ ROS | ↓            | Oxidation†         |                     | ✓              | ✓                    | MG132           | [79]            |
|                          | ROS       | ↓            | S-glutathionylation† (human Cys258 †) | ERK                  | ✓              | ✓                    | MG132           | [81]            |
|                          | Glucocorticoid | ↑ |                    |                     | ✓              | ✓                    | MG132; LLnL    | [60]            |
|                          | EGF plus Lactoferrin | ↓ |                    |                     | ✓              | ✓                    | MG132           | [32]            |
|                          | Angiotensin II/ FKA | ↓ |                    |                     | ✓              | ✓                    | Bortezomib      | [33]            |
|                          | CaMKII inhibition | ↓ |                    |                     | ✓              | ✓                    | MG132           | [64]            |
|                          | Luteolin/ Superoxide | ↓ |                    |                     | ✓              | ✓                    | MG132           | [80]            |
| DUSP2                    | ERK4      | ↑            |                    |                      |                |                      |                 |                 |
| DUSP4                    | LPS       | ↑            | Phosphorylation† (human Ser386 †/Ser391 †) | ERK                  | ✓              | ✓                    | MG132, PS-341   | [57]            |
|                          | ERK inhibitor | ↓ | Phosphorylation† (human Ser386 †/Ser391 †); Ubiquitination† | ERK                  | ✓              | ✓                    | MG132           | [67]            |
|                          | Ca2⁺/ Oxidative stress | ↓ | Oxidation†       |                     | ✓              | ✓                    |                 | [68]            |
|                          | 8-Bromo-cAMP | ↑ |                    |                     | ✓              | ✓                    | MG132           | [58]            |
|                          | Senescence | ↑            |                    |                     | ✓              | ✓                    | MG132           | [37]            |
|                          | DUSP5     | ↑            | Ubiquitination†    |                     | ✓              | ✓                    | MG132           | [39]            |
Table 2. Cont.

| Stimuli                  | Stability | Modification                        | Modification Enzyme | Experimental Methods | Reference |
|--------------------------|-----------|-------------------------------------|---------------------|----------------------|-----------|
| **DUSP6**                | Serum     | ↓ \(\text{Phosphorylation}^{†/\text{Ubiquitination}}\) (human Ser159^{†}/Ser197^{†}) | ERK                 | ✓ ✓ ✓                | LLnL; Lactacystin [70,71] |
| **ROS**                  | ↓         | \(\text{Phosphorylation}^{†}\) (human Ser159^{†}/Ser197^{†}), Ubiquitination^{†} | ✓ ✓ ✓                | MG132                | [43]      |
| **PDGF**                 | ↓         | \(\text{Phosphorylation}^{†}\) (human Ser174^{†}), Ubiquitination^{†} | ✓ ✓ ✓                | MG132                | [74]      |
| **P2X7 nucleotide, EGF** | ↓         | \(\text{Phosphorylation}^{†}\) (human Ser197^{†}) | ERK                 | ✓ ✓ ✓                | MG132 [71] |
| **Insulin**              | ↓         | \(\text{Phosphorylation}^{†}\) (human Ser159^{†}/Ser197^{†}) | ERK                 | ✓ ✓ ✓                | [72]      |
| **Amino acid, insulin, IGF-1/mTOR** | ↓         | \(\text{Phosphorylation}^{†}\) (human Ser159^{†}) | ✓ ✓ ✓                | MG132                | [73]      |
| **PKCδ downregulation**  | ↓         | Ubiquitination^{†} | SPOP                | ✓ ✓ ✓                | MG132 [46] |
| **TSH**                  | ↑         |                                   |                     | MG132                | [44]      |
| **Metformin/ AMP-activated protein kinase** | ↓         |                                 |                     | MG132 [45] |
| **EGF plus Lactoferrin** | ↓         |                                   |                     | MG132                | [32]      |
| **DUSP7**                | Hypoxic stress/ HIFs | ↓ Ubiquitination^{†} | SPOP                | ✓ ✓ ✓                | MG132 [47] |
| **DUSP8**                | Anisomycin | ↓ \(\text{Phosphorylation}^{†/\text{Ubiquitination}^{†}}\) | JNK                 | ✓ ✓ ✓                | Lactacystin [52] |
| **DUSP9**                | LincU upregulation | ↑ Ubiquitination^{†} |                     | ✓ ✓ ✓                | MG132 [53] |
| **DUSP10**               | Insulin   | ↑ \(\text{Phosphorylation}^{†}\) (human Ser224^{†}/Ser230^{†}) | mTORC2              | ✓ ✓ ✓                | [75]      |
| **DUSP14**               | TCR signaling | (Activity^{†}) | Methylation^{†} (human Arg17^{†}/Arg38^{†}/Arg45^{†}), Ubiquitination^{†} (human Lys103^{†}) | PRMT5; TRAF2 | ✓ ✓ ✓ | [86,87] |
| **DUSP16**               | ERK upregulation | ↑ \(\text{Phosphorylation}^{†}\) (human Ser446^{†}) | ERK                 | ✓ ✓ ✓                | MG132; MG115 [77,78] |

\(^†\) denotes the amino acid residue is conserved in both human and mouse proteins. LPS denotes lipopolysaccharides. TSH denotes thyroid-stimulating hormone. GSSG denotes glutathione disulfide.
The protein stability of DUSP1, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, and DUSP16 are regulated by ubiquitin-mediated proteasomal degradation. Protein stability of DUSP2 and DUSP10 is increased by ERK and mTORC2, respectively [65,75]; however, it is unclear whether ubiquitination is involved in the degradation of these two phosphatases. To date, only three ubiquitin E3 ligases and one deubiquitinase (also named ubiquitin-specific peptidase (USP)) for degradation of DUSPs have been identified. The ubiquitin E3 ligases CUL1 and Atrogin-1 are responsible for DUSP1 ubiquitination; the ubiquitin E3 ligase SPOP is responsible for DUSP7 ubiquitination [33,47,54]. The deubiquitinase for DUSP1 is USP49 [34]. Additional ubiquitin E3 ligases and deubiquitinases for controlling proteasomal degradation of DUSPs await to be identified. The ubiquitination/proteasomal degradation of DUSPs are usually regulated by phosphorylation. Although MAPKs are dephosphorylated by DUSPs, MAPKs also reciprocally control protein stability of DUSPs and their downstream signaling pathways. One major kinase for DUSPs is ERK. Transient activation of ERK phosphorylates DUSP1 on Ser359 and Ser364 residues to stabilize DUSP1, providing a negative feedback that attenuates ERK activity [56]. In contrast, sustained ERK activity induces DUSP1 Ser296/323 phosphorylation and subsequent protein degradation, resulting in further enhancement of ERK signaling [27,54]. Consistently, both sustained ERK activation and decreased DUSP1 protein levels are observed in cancer cells [102,103]. Moreover, ERK phosphorylates DUSP6 on Ser159 and Ser197 residues, facilitating DUSP6 proteasomal degradation [70]. The MEK/ERK pathway also mediates DUSP6 Ser174 phosphorylation and subsequently induces DUSP6 degradation [74]. Unlike the inhibitory effect of ERK on DUSP6, ERK increases DUSP4 protein stability by phosphorylating DUSP4 on Ser386 and Ser391 residues [57]. Enhancement of DUSP4 protein levels leads to inhibition of ERK activity. Similarly, ERK protects DUSP16 from proteasomal degradation by phosphorylating DUSP16 on Ser446 residue [77]. DUSP16 preferentially dephosphorylates JNK and maybe p38 compared to ERK [17,76], suggesting that ERK-mediated DUSP16 induction negatively regulates the activation of JNK or maybe p38. Besides ERK, mTOR also regulates protein stability of DUSPs. mTORC2 phosphorylates DUSP10 on Ser224 and Ser230 residues and subsequently enhances DUSP10 protein stability, leading to reduction of p38 activity [75]. Moreover, mTOR signaling also induces DUSP6 Ser159 phosphorylation, resulting in proteasomal degradation of DUSP6 [73].

In addition to phosphorylation, oxidation of DUSPs also induces protein degradation. Asbestos or TNFα stimulation generates ROS that oxidizes DUSP1 and induces DUSP1 proteasomal degradation [79,82]. Cd²⁺-induced oxidative stress triggers DUSP4 oxidation by glutathione disulfide (GSSG), resulting in protein degradation of DUSP4 [83].

Ubiquitination not only controls protein stability but also induces protein activity. The ubiquitin E3 ligase TRAF2-mediated Lys63-linked ubiquitination of DUSP14 enhances its phosphatase activity. It would be interesting to study whether Lys63-linked ubiquitination also regulates the activity of other DUSPs.

To our knowledge, eight DUSPs (DUSP1, DUSP4, DUSP5, DUSP6, DUSP7, DUSP8, DUSP9, and DUSP16) are known to be degraded by the proteasome, and it is important to understand whether other members of the DUSP family are also regulated by ubiquitin-mediated proteasomal degradation. Lastly, it would be useful to study whether other modifications, such as sumoylation, neddylation, acetylation, and glycosylation also control DUSP ubiquitination and protein stability.

Author Contributions: Conceptualization, T.-H.T.; writing—original draft preparation, H.-F.C. and H.-C.C.; writing—review and editing, H.-C.C. and T.-H.T.; supervision, H.-C.C. and T.-H.T.

Funding: This work was supported by grants from the National Health Research Institutes, Taiwan (IM-107-PP-01 and IM-107-SP-01, to T.H.T) and the Ministry of Science and Technology, Taiwan (107-2314-B-400-027 and 107-2321-B-400-013 to T.H.T.; 107-2628-B-400-001 to H.-C.C.).

Acknowledgments: T.-H.T. is a recipient of the Taiwan Bio-Development Foundation (TBF) Chair in Biotechnology.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Abbreviations

Ub ubiquitination  
DUSP dual-specificity phosphatase  
MKP MAP kinase phosphatase  
MAPK mitogen-activated protein kinase  
KIM kinase-interacting motif  
Skp2 S-phase kinase-associated protein  
Cks1 cyclin-dependent kinase regulatory subunit 1  
FoxM1 forkhead box M1  
STAT1 signal transducer and activator of transcription 1  
LncRNA long non-coding RNA  
EGF epidermal growth factor  
PRMT5 protein arginine methyltransferase 5  
T FH T follicular helper cell  
EAE experimental autoimmune encephalomyelitis  
SLE systemic lupus erythematosus  
SPOP Speckle-type POZ protein  
PDGF-BB platelet-derived growth factor-B chains

References

1. Widmann, C.; Gibson, S.; Jarpe, M.B.; Johnson, G.L. Mitogen-activated protein kinase: Conservation of a three-kinase module from yeast to human. *Physiol. Rev.* 1999, 79, 143–180. [CrossRef]
2. Raman, M.; Chen, W.; Cobb, M.H. Differential regulation and properties of MAPKs. *Oncogene* 2007, 26, 3100–3112. [CrossRef] [PubMed]
3. Chen, Y.R.; Meyer, C.F.; Tan, T.H. Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in γ radiation-induced apoptosis. *J. Biol. Chem.* 1996, 271, 631–634. [CrossRef]
4. Chen, Y.R.; Wang, X.; Templeton, D.; Davis, R.J.; Tan, T.H. The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and γ radiation: Duration of JNK activation may determine cell death and proliferation. *J. Biol. Chem.* 1996, 271, 31929–31936. [CrossRef]
5. MacCorkle, R.A.; Tan, T.H. Mitogen-activated protein kinases in cell-cycle control. *Cell Biochem. Biophys.* 2005, 43, 451–461. [CrossRef]
6. Cargnello, M.; Roux, P.P. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. *Microbiol. Mol. Biol. Rev.* 2011, 75, 50–83. [CrossRef] [PubMed]
7. Chen, Y.R.; Tan, T.H. The c-Jun N-terminal kinase pathway and apoptotic signaling. *Int. J. Oncol.* 2000, 16, 651–662. [CrossRef]
8. Marshall, C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. *Curr. Opin. Genet. Dev.* 1994, 4, 82–89. [CrossRef]
9. Wada, T.; Penninger, J.M. Mitogen-activated protein kinases in apoptosis regulation. *Oncogene* 2004, 23, 2838–2849. [CrossRef]
10. Turjanski, A.G.; Vaque, J.P.; Gutkind, J.S. MAP kinases and the control of nuclear events. *Oncogene* 2007, 26, 3240–3253. [CrossRef]
11. Kyriakis, J.M.; Avruch, J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. *Physiol. Rev.* 2001, 81, 807–869. [CrossRef]
12. Dhillon, A.S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer. *Oncogene* 2007, 26, 3279–3290. [CrossRef]
13. Caunt, C.J.; Keyse, S.M. Dual-specificity MAP kinase phosphatases (MKPs): Shaping the outcome of MAP kinase signalling. *FASEB J.* 2013, 28, 489–504. [CrossRef]
14. Farooq, A.; Zhou, M.M. Structure and regulation of MAPK phosphatases. *Cell. Signal.* 2004, 16, 769–779. [CrossRef]
15. Huang, C.Y.; Tan, T.H. DUSPs, to MAP kinases and beyond. *Cell Biosci.* 2012, 2, 24. [CrossRef]
16. Mandl, M.; Slack, D.N.; Keyse, S.M. Specific inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-specificity protein phosphatase DUSP5. *Mol. Cell. Biol.* 2005, 25, 1830–1845. [CrossRef]

17. Masuda, K.; Shima, H.; Watanabe, M.; Kikuchi, K. MKP-7, a novel mitogen-activated protein kinase phosphatase, functions as a shuttle protein. *J. Biol. Chem.* 2001, 276, 39002–39011. [CrossRef]

18. Karlsson, M.; Mathers, J.; Dickinson, R.J.; Mandl, M.; Keyse, S.M. Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal. *J. Biol. Chem.* 2004, 279, 41882–41891. [CrossRef] [PubMed]

19. Tanoue, T.; Adachi, M.; Moriguchi, T.; Nishida, E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. *Nat. Cell Biol.* 2000, 2, 110–116. [CrossRef]

20. Welchman, R.L.; Gordon, C.; Mayer, R.J. Ubiquitin and ubiquitin-like proteins as multifunctional signals. *Nat. Rev. Mol. Cell Biol.* 2005, 6, 599–609. [CrossRef] [PubMed]

21. Dikic, I.; Wakatsuki, S.; Walters, K.J. Ubiquitin-binding domains -from structures to functions. *Nat. Rev. Mol. Cell Biol.* 2009, 10, 659–671. [CrossRef]

22. Malynn, B.A.; Ma, A. Ubiquitin makes its mark on immune regulation. *Immunity* 2010, 33, 843–852. [CrossRef]

23. Kwon, Y.T.; Ciechanover, A. The ubiquitin code in the ubiquitin-proteasome system and autophagy. *Trends Biochem. Sci.* 2017, 42, 873–886. [CrossRef] [PubMed]

24. Slack, D.N.; Seternes, O.M.; Gabrielsen, M.; Keyse, S.M. Distinct binding determinants for ERK2/p38α and JNK map kinases mediate catalytic activation and substrate selectivity of map kinase phosphatase-1. *J. Biol. Chem.* 2001, 276, 16491–16500. [CrossRef] [PubMed]

25. Patterson, K.L.; Brummer, T.; O’Brien, P.M.; Daly, R.J. Dual-specificity phosphatases: Critical regulators with diverse cellular targets. *Biochem. J.* 2009, 418, 475–489. [CrossRef]

26. Ma, R.Y.; Tong, T.H.; Cheung, A.M.; Tsang, A.C.; Leung, W.Y.; Yao, K.M. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. *J. Cell Sci.* 2005, 118, 795–806. [CrossRef] [PubMed]

27. Lin, Y.W.; Chuang, S.M.; Yang, J.L. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. *J. Biol. Chem.* 2003, 278, 21534–21541. [CrossRef] [PubMed]

28. Calvisi, D.F.; Pinna, F.; Meloni, F.; Ladu, S.; Pellegrino, R.; Sini, M.; Daino, L.; Simile, M.; Virdis, P.; et al. Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma. *Cancer Res.* 2008, 68, 4192–4200. [CrossRef] [PubMed]

29. Major, M.L.; Lepe, R.; Costa, R.H. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. *Mol. Cell. Biol.* 2004, 24, 2649–2661. [CrossRef]

30. Wang, I.C.; Chen, Y.J.; Hughes, D.; Petrovic, V.; Major, M.L.; Park, H.J.; Tan, Y.; Ackerson, T.; Costa, R.H. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. *Mol. Cell. Biol.* 2005, 25, 10875–10894. [CrossRef] [PubMed]

31. Choi, B.H.; Hur, E.M.; Lee, J.H.; Jun, D.J.; Kim, K.T. Protein kinase Cδ-mediated proteasomal degradation of MAP kinase phosphatase-1 contributes to glutamate-induced neuronal cell death. *J. Cell Sci.* 2006, 119, 1329–1340. [CrossRef] [PubMed]

32. Geetha, N.; Mihaly, J.; Stockenhuber, A.; Blasi, F.; Uhrin, P.; Binder, B.R.; Freissmuth, M.; Breuss, J.M. Signal integration and coincidence detection in the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) cascade: Concomitant activation of receptor tyrosine kinases and of LRP-1 leads to sustained ERK phosphorylation via down-regulation of dual specificity phosphatases (DUSP1 and -6). *J. Biol. Chem.* 2011, 286, 25663–25674. [PubMed]

33. Xie, P.; Guo, S.; Fan, Y.; Zhang, H.; Gu, D.; Li, H. Atrogin-1/MAFbx enhances simulated ischemia/reperfusion-induced apoptosis in cardiomyocytes through degradation of MAPK phosphatase-1 and sustained JNK activation. *J. Biol. Chem.* 2009, 284, 5488–5496. [CrossRef] [PubMed]

34. Zhang, W.; Zhang, Y.; Zhang, H.; Zhao, Q.; Liu, Z.; Xu, Y. USP49 inhibits ischemia-reperfusion-induced cell viability suppression and apoptosis in human AC16 cardiomyocytes through DUSP1-JNK1/2 signaling. *J. Cell. Physiol.* 2019, 234, 6529–6538. [CrossRef]
35. Qin, X.Y.; Zhang, Y.L.; Chi, Y.F.; Yan, B.; Zeng, X.J.; Li, H.H.; Liu, Y. Angiotensin II regulates Th1 cell differentiation through angiotensin II type 1 receptor-PKA-mediated activation of proteasome. *Cell. Physiol. Biochem.* 2018, 45, 1366–1376. [CrossRef]

36. Chen, P.; Hutter, D.; Yang, X.; Gorospe, M.; Davis, R.J.; Liu, Y. Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically. *J. Biol. Chem.* 2001, 276, 29440–29449. [CrossRef]

37. Torres, C.; Francis, M.K.; Lorenzini, A.; Tresini, M.; Cristofalo, V.J. Metabolic stabilization of MAP kinase phosphatase-2 in senescence of human fibroblasts. *Exp. Cell Res.* 2003, 290, 195–206. [CrossRef]

38. Gomez, N.V.; Gorostizaga, A.B.; Mori Sequeiros Garcia, M.M.; Brion, L.; Acquier, A.; Gonzalez-Calvar, S.I.; Mendez, C.F.; Podesta, E.J.; Paz, C. MAPK phosphatase-2 (MKP-2) is induced by hCG and plays a role in the regulation of CYP1A1 expression in MA-10 Leydig cells. *Endocrinology* 2013, 154, 1488–1500. [CrossRef]

39. Kucharska, A.; Rushworth, L.K.; Staples, C.; Morrice, N.A.; Keyse, S.M. Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. *Cell. Signal.* 2009, 21, 1794–1805. [CrossRef]

40. Kidger, A.M.; Rushworth, L.K.; Stellzig, J.; Davidson, J.; Bryant, C.J.; Bayley, C.; Caddy, E.; Rogers, T.; Keyse, S.M.; Caunt, C.J. Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling. *Proc. Natl. Acad. Sci. USA* 2017, 114, E317–E326. [CrossRef]

41. Groom, L.A.; Sneddon, A.A.; Alesii, D.R.; Dowd, S.; Keyse, S.M. Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase. *EMBO J.* 1996, 15, 3621–3632. [CrossRef][PubMed]

42. Muda, M.; Boschert, U.; Dickinson, R.; Martinou, J.C.; Martinou, I.; Camps, M.; Schlegel, W.; Arkinstall, S. MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase. *J. Biol. Chem.* 1996, 271, 4319–4326. [CrossRef]

43. Chan, D.W.; Liu, V.W.; Tsao, G.S.; Yao, K.M.; Furukawa, T.; Chan, K.K.; Ngan, H.Y. Loss of MKP3 mediated regulation of proliferating signaling. *Cancer Cell* 2014, 25, 664–676. [CrossRef]

44. Martin, M.J.; Hayward, R.; Viros, A.; Marais, R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. *Cancer Discov.* 2012, 2, 344–355. [CrossRef]

45. Lonne, G.K.; Masoumi, K.C.; Lennartsson, J.; Larsson, C. Protein kinase Cδ supports survival of MDA-MB-231 breast cancer cells by suppressing the ERK1/2 pathway. *J. Biol. Chem.* 2009, 284, 33456–33465. [CrossRef][PubMed]

46. Li, G.; Ci, W.; Karmakar, S.; Chen, K.; Dhar, R.; Fan, Z.; Guo, Z.; Zhang, J.; Ke, Y.; Wang, L.; et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. *Cancer Cell* 2014, 25, 455–468. [CrossRef][PubMed]

47. Chen, P.; Hutter, D.; Yang, X.; Gorospe, M.; Davis, R.J.; Liu, Y. Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically. *J. Biol. Chem.* 2001, 276, 29440–29449. [CrossRef]

48. Cotsiki, M.; Oehrl, W.; Samiotaki, M.; Theodosiou, A.; Panayotou, G. Phosphorylation of the M3 protein-tyrosine phosphatase. *Proc. Natl. Acad. Sci. USA* 2001, 98, 15436–15441. [CrossRef][PubMed]

49. Muda, M.; Theodosiou, A.; Rodrigues, N.; Boschert, U.; Camps, M.; Gillieron, C.; Davies, K.; Ashworth, A.; Arkinstall, S. The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases. *J. Biol. Chem.* 1996, 271, 27205–27208. [CrossRef][PubMed]

50. Chen, Y.R.; Shrivastava, A.; Tan, T.H. Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. *Oncoogene* 2001, 20, 367–374. [CrossRef][PubMed]

51. Barbacid, M.; Vazquez, D. 6-Hansisomycin binding to eukaryotic ribosomes. *J. Mol. Biol.* 1974, 84, 603–623. [CrossRef]
55. Moosavi, S.M.; Prabhala, P.; Ammit, A.J. Role and regulation of MKP-1 in airway inflammation. *Respir. Res.* 2017, 18, 154. [CrossRef]

56. Brondello, J.M.; Pouyssegur, J.; McKenzie, F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. *Science* 1999, 286, 2514–2517. [CrossRef]

57. Crowell, S.; Wancket, L.M.; Shakibi, Y.; Xu, P.; Xue, J.; Samavati, L.; Nelin, L.D.; Liu, Y. Post-translational regulation of mitogen-activated protein kinase phosphatase (MKP)-1 and MKP-2 in macrophages following lipopolysaccharide stimulation: The role of the C termini of the phosphatases in determining their stability. *J. Biol. Chem.* 2014, 289, 28753–28764. [CrossRef]

58. Liu, R.; Zheng, H.Q.; Zhou, Z.; Dong, J.T.; Chen, C. KLF5 promotes breast cell survival partially through fibroblast growth factor-binding protein 1-pERK-mediated dual specificity MKP-1 protein phosphorylation and stabilization. *J. Biol. Chem.* 2009, 284, 16791–16798. [CrossRef]

59. Chen, P.; Li, J.; Barnes, J.; Kokkonen, G.C.; Lee, J.C.; Liu, Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. *J. Immunol.* 2002, 169, 6408–6416. [CrossRef]

60. Kassel, O.; Sancono, A.; Kratzschmar, J.; Kreft, B.; Stassen, M.; Cato, A.C. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. *EMBO J.* 2001, 20, 7108–7116. [CrossRef]

61. Swantek, J.L.; Cobb, M.H.; Geppert, T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor α (TNF-α) translation: Glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. *Mol. Cell. Biol.* 1997, 17, 6274–6282. [CrossRef]

62. Kontoyiannis, D.; Pasparakis, M.; Pizarro, T.T.; Cominelli, F.; Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies. *Immunity* 1999, 10, 387–398. [CrossRef]

63. Jacob, A.; Smolenski, A.; Lohmann, S.M.; Begum, N. MKP-1 expression and stabilization and cGK I protein in liver cells. *Mol. Cell. Biol.* 1999, 19, 154. [CrossRef]

64. Jacob, A.; Smolenski, A.; Lohmann, S.M.; Begum, N. MKP-1 expression and stabilization and cGK I protein in liver cells. *Mol. Cell. Biol.* 1999, 19, 154. [CrossRef]

65. Jacob, A.; Smolenski, A.; Lohmann, S.M.; Begum, N. MKP-1 expression and stabilization and cGK I protein in liver cells. *Mol. Cell. Biol.* 1999, 19, 154. [CrossRef]

66. Jacob, A.; Smolenski, A.; Lohmann, S.M.; Begum, N. MKP-1 expression and stabilization and cGK I protein in liver cells. *Mol. Cell. Biol.* 1999, 19, 154. [CrossRef]

67. Peng, D.J.; Zhou, J.Y.; Wu, G.S. Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. *Cell Cycle* 2010, 9, 4650–4655. [CrossRef]

68. Hijiya, N.; Tsukamoto, Y.; Nakada, C.; Tung Nguyen, L.; Kai, T.; Matsuura, K.; Shibata, K.; Inomata, M.; Cadalbert, L.C.; Sloss, C.M.; Cunningham, M.R.; Al-Mutairi, M.; McIntire, A.; Shipley, J.; Plevin, R. Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. *Sci. Rep.* 2017, 7, 43471. [CrossRef]

69. Brondello, J.M.; Brunet, A.; Pouyssegur, J.; McKenzie, F.R. The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44MAPK cascade. *J. Biol. Chem.* 1997, 272, 1368–1376. [CrossRef]

70. Peng, D.J.; Zhou, J.Y.; Wu, G.S. Post-translational regulation of mitogen-activated protein kinase phosphatase-2 (MKP-2) by ERK. *Cell Cycle* 2010, 9, 4650–4655. [CrossRef]

71. Marchetti, S.; Chambard, J.C.; Touboul, T.; Roux, D.; Pouyssegur, J.; Pages, G. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. *Mol. Cell. Biol.* 2005, 25, 854–864. [CrossRef]

72. Queipo, M.J.; Gil-Redondo, J.C.; Morente, V.; Ortega, F.; Miras-Portugal, M.T.; Delicado, E.G.; Perez-Sen, R. P2X7 nucleotide and EGF receptors exert dual modulation of the dual-specificity phosphatase 6 (MKP-3) in granule neurons and astrocytes, contributing to negative feedback on ERK signaling. *Front. Mol. Neurosci.* 2017, 10, 448. [CrossRef]

73. Bermudez, O.; Marchetti, S.; Pages, G.; Gimond, C. Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. *Oncogene* 2008, 27, 3685–3691. [CrossRef]
74. Jurek, A.; Amagasaki, K.; Gembarska, A.; Heldin, C.H.; Lennartsson, J. Negative and positive regulation of MAPK phosphatase 3 controls platelet-derived growth factor-induced Erk activation. *J. Biol. Chem.* **2009**, *284*, 4626–4634. [CrossRef]

75. Benavides-Serrato, A.; Anderson, L.; Holmes, B.; Cloninger, C.; Artinian, N.; Bashir, T.; Gera, J. mTORC2 modulates feedback regulation of p38 MAPK activity via DUSP10/MKP5 to confer differential responses to PP242 in glioblastoma. *Genes Cancer* **2014**, *5*, 393–406.

76. Tanoue, T.; Yamamoto, T.; Maeda, R.; Nishida, E. A novel MAPK phosphatase MKP-7 acts preferentially on JNK/SAPK and p38 α and β MAPKs. *J. Biol. Chem.* **2001**, *276*, 26629–26639. [CrossRef]

77. Katagiri, C.; Masuda, K.; Urano, T.; Yamashita, K.; Araki, Y.; Kikuchi, K.; Shima, H. Phosphorylation of Ser-446 determines stability of MKP-7. *J. Biol. Chem.* **2005**, *280*, 14716–14722. [CrossRef]

78. Masuda, K.; Shima, H.; Katagiri, C.; Kikuchi, K. Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK specific phosphatase, at Ser-446. *J. Biol. Chem.* **2003**, *278*, 32448–32456. [CrossRef]

79. Kamata, H.; Honda, S.; Maeda, S.; Chang, L.; Hirata, H.; Karin, M. Reactive oxygen species promote TNFα-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. *Cell* **2005**, *120*, 649–661. [CrossRef]

80. Bai, L.; Xu, X.; Wang, Q.; Xu, S.; Ju, W.; Wang, X.; Chen, W.; He, W.; Tang, H.; Lin, Y. A superoxide-mediated mitogen-activated protein kinase phosphatase-1 degradation and c-Jun NH2-terminal kinase activation pathway for luteolin-induced lung cancer cytotoxicity. *Mol. Pharmacol.* **2012**, *81*, 549–555. [CrossRef]

81. Kim, H.S.; Ullevig, S.L.; Zamora, D.; Lee, C.F.; Asmis, R. Redox regulation of MKP phosphatase 1 controls monocyte migration and macrophage recruitment. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, E2803–E2812. [CrossRef]

82. Teply, L.A.; Carter, A.B. Differential expression and oxidation of MKP-1 modulates TNF-α gene expression. *Am. J. Respir. Cell Mol. Biol.* **2007**, *37*, 366–374. [CrossRef]

83. Barajas-Espinosa, A.; Basye, A.; Jesse, E.; Yan, H.; Quan, D.; Chen, C.A. Redox activation of DUSP4 by N-acetylcysteine protects endothelial cells from Cd2+−induced apoptosis. *Free Radic. Biol. Med.* **2014**, *74*, 188–199. [CrossRef]

84. Marti, F.; Krause, A.; Post, N.H.; Lyddain, C.; Dupont, B.; Sadelayin, M.; King, P.D. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. *J. Immunol.* **2001**, *166*, 197–206. [CrossRef]

85. Yang, C.Y.; Li, J.P.; Chiu, L.L.; Lan, J.L.; Chen, D.Y.; Huang, H.C.; Tan, T.H. Dual-specificity phosphatase 14 (DUSP14/MKP6) negatively regulates TCR signaling by inhibiting TAB1 activation. *J. Immunol.* **2014**, *192*, 1547–1557. [CrossRef]

86. Yang, C.Y.; Chiu, L.L.; Tan, T.H. TRAF2-mediated Lys63-linked ubiquitination of DUSP14/MKP6 is essential for its phosphatase activity. *Cell. Signal.* **2016**, *28*, 145–151. [CrossRef]

87. Yang, C.Y.; Chiu, L.L.; Chang, C.C.; Huang, H.C.; Tan, T.H. Induction of DUSP14 ubiquitination by PRMT5-mediated arginine methylation. *FASEB J.* **2014**, *28*, 1547–1557. [CrossRef]

88. Berman, O.; Pages, G.; Gimond, C. The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. *Am. J. Physiol. Cell Physiol.* **2010**, *299*, C189–C202. [CrossRef]

89. Hsu, W.C.; Chen, M.Y.; Hsu, S.C.; Huang, L.R.; Kao, C.Y.; Cheng, W.H.; Pan, C.H.; Wu, M.S.; Yu, G.Y.; Hung, M.S.; et al. DUSP6 mediates T cell receptor-engaged glycolysis and restrains Tfh cell differentiation. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, E8027–E8036. [CrossRef]

90. Ruan, J.W.; Statt, S.; Huang, C.T.; Tsai, Y.T.; Kuo, C.C.; Chan, H.L.; Liao, Y.C.; Tan, T.H.; Kao, C.Y. Dual-specificity phosphatase 6 deficiency regulates gut microbiome and transcriptome response against diet-induced obesity in mice. *Nat. Microbiol.* **2016**, *2*, 16220. [CrossRef]

91. Okudela, K.; Yazawa, T.; Woo, T.; Sakaeda, M.; Ishii, J.; Mitsui, H.; Shimoyamada, H.; Sato, H.; Tajiri, M.; Ogawa, N.; et al. Down-regulation of DUSP6 expression in lung cancer: Its mechanism and potential role in carcinogenesis. *Am. J. Pathol.* **2009**, *175*, 867–881. [CrossRef]

92. Furukawa, T.; Sunamura, M.; Motoi, F.; Matsuno, S.; Horii, A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. *Am. J. Pathol.* **2003**, *162*, 1807–1815. [CrossRef]

93. Hou, P.C.; Li, Y.H.; Lin, S.C.; Lin, S.C.; Lee, J.C.; Lin, B.W.; Liou, J.P.; Chang, J.Y.; Kuo, C.C.; Liu, Y.M.; et al. Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. *Cancer Res.* **2017**, *77*, 4305–4316. [CrossRef]
94. Wang, J.Y.; Yeh, C.L.; Chou, H.C.; Yang, C.H.; Fu, Y.N.; Chen, Y.T.; Cheng, H.W.; Huang, C.Y.; Liu, H.P.; Huang, S.F.; et al. Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer. *J. Biol. Chem.* 2011, 286, 10177–10184. [CrossRef]

95. Chen, Y.R.; Chou, H.C.; Yang, C.H.; Chen, H.Y.; Liu, Y.W.; Lin, T.Y.; Yeh, C.L.; Chao, W.T.; Tsou, H.H.; Chuang, H.C.; et al. Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration. *Oncogene* 2017, 36, 6509–6517. [CrossRef]

96. Shin, S.H.; Park, S.Y.; Kang, G.H. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. *Am. J. Pathol.* 2013, 182, 1275–1285. [CrossRef]

97. Togel, L.; Nightingale, R.; Wu, R.; Chueh, A.C.; Al-Obaidi, S.; Luk, I.; Davalos-Salas, M.; Chionh, F.; Murone, C.; Buchanan, D.D.; et al. DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. *Sci. Rep.* 2018, 8, 1767. [CrossRef]

98. Li, J.P.; Yang, C.Y.; Chuang, H.C.; Lan, J.L.; Chen, D.Y.; Chen, Y.M.; Wang, X.; Chen, A.J.; Belmont, J.W.; Tan, T.H. The phosphatase JKAP/DUSP22 inhibits T-cell receptor signalling and autoimmunity by inactivating Lck. *Nat. Commun.* 2014, 5, 3618. [CrossRef]

99. Chuang, H.C.; Chen, Y.M.; Hung, W.T.; Li, J.P.; Chen, D.Y.; Lan, J.L.; Tan, T.H. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. *Oncotarget* 2016, 7, 57593–57605. [CrossRef]

100. Melard, P.; Idrissi, Y.; Andrique, L.; Poglio, S.; Prochazkova-Carlotti, M.; Berhouet, S.; Boucher, C.; Laharanne, E.; Chevret, E.; Pham-Ledard, A.; et al. Molecular alterations and tumor suppressive function of the DUSP22 (Dual Specificity Phosphatase 22) gene in peripheral T-cell lymphoma subtypes. *Oncotarget* 2016, 7, 68734–68748. [CrossRef]

101. Feldman, A.L.; Dogan, A.; Smith, D.I.; Law, M.E.; Ansell, S.M.; Johnson, S.H.; Porcher, J.C.; Ozsan, N.; Wieben, E.D.; Eckloff, B.W.; et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. *Blood* 2011, 117, 915–919. [CrossRef] [PubMed]

102. Gioeli, D.; Mandell, J.W.; Petroni, G.R.; Frierson, H.F., Jr.; Weber, M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. *Cancer Res.* 1999, 59, 279–284. [PubMed]

103. Hoshino, R.; Chatani, Y.; Yamori, T.; Tsuruo, T.; Oka, H.; Yoshida, O.; Shimada, Y.; Ari-i, S.; Wada, H.; Fujimoto, J.; et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. *Oncogene* 1999, 18, 813–822. [CrossRef] [PubMed]